Semaglutide × HbA1c

Study 1 · Included

Generic semaglutide is as effective as innovator version for diabetes control

Rct

Comparison

Participants received generic semaglutide for 24 weeks in a step wise dose escalation. · Participants received innovator semaglutide for 24 weeks in a step wise dose escalation.

Duration / follow-up

24 weeks

Study 2 · Limited

GLP-1 agonists reduce heart fat thickness in diabetes.

Comparison

Patients received semaglutide as part of their treatment regimen. · Patients received dulaglutide as part of their treatment regimen. · Patients received metformin as the control treatment.

Duration / follow-up

12 weeks

Study 3 · Included

Higher semaglutide doses improve glucose control in type 2 diabetes

Rct

Comparison

Participants received 2 mg of semaglutide weekly for 40 weeks. · Participants received 8 mg of semaglutide weekly for 40 weeks. · Participants received 16 mg of semaglutide weekly for 40 weeks. · Participants received a matching placebo for 40 weeks.

Duration / follow-up

9 weeks

Study 4 · Included

Novel Semaglutide Injection Shows Non-Inferior Glycemic Control

Rct

Comparison

Patients received once weekly semaglutide injection for 24 weeks. · Patients received reference semaglutide injection for 24 weeks.

Duration / follow-up

24 weeks

Study 5 · Included

Once-weekly semaglutide improves glycemic control in Korean adults with T2D

Rct

Comparison

Participants received OW s.c. semaglutide 0.5 mg. · Participants received OW s.c. semaglutide 1.0 mg. · Participants received OD oral sitagliptin 100 mg.

Duration / follow-up

30 weeks

Study 6 · Included

Oral semaglutide improves glycemic control in type 2 diabetes

Rct

Comparison

Participants received once daily oral semaglutide 3 mg. · Participants received once daily oral semaglutide 7 mg. · Participants received once daily oral semaglutide 14 mg. · Participants received once daily oral sitagliptin 100 mg.

Duration / follow-up

26 weeks

Study 7 · Included

Oral semaglutide reduces cardiovascular events in type 2 diabetes

Rct

Comparison

Participants receiving oral semaglutide as an adjunct to standard of care treatment. · Participants receiving placebo treatment.

Duration / follow-up

208 weeks

Study 8 · Included

Semaglutide improves glycemic control more than insulin aspart in type 2 diabetes

Rct

Comparison

Participants received once weekly semaglutide as add on to optimized insulin glargine and metformin. · Participants received thrice daily insulin aspart as add on to optimized insulin glargine and metformin.

Duration / follow-up

52 weeks

Study 9 · Included

Semaglutide reduces cardiovascular events and body weight in T2D

Rct

Comparison

Participants received semaglutide to evaluate cardiovascular, metabolic, and safety outcomes. · Participants received a dose matched placebo as a comparator to semaglutide.

Duration / follow-up

3380 weeks

Study 10 · Included

Switching to Semaglutide Improves Diabetes Management

Rct

Comparison

Patients switched from dpp 4 inhibitors to oral semaglutide · Patients continued on dpp 4 inhibitors

Duration / follow-up

24 weeks

Study 11 · Included

Tirzepatide shows greater HbA1c and weight reduction than Semaglutide

Rct

Comparison

Participants received 5 mg of Tirzepatide. · Participants received 10 mg of Tirzepatide. · Participants received 15 mg of Tirzepatide. · Participants received 1 mg of Semaglutide.

Duration / follow-up

40 weeks